Hot Topic of the Month | A Standout New Drug Shines at 2026 ASCO!

The 2026 ASCO Annual Meeting witnessed a real highlight: Daraxonrasib, a pan-RAS non-degrading molecular glue from Revolution Medicines, stole the show. Its presentation ended with a standing ovation from all attending experts!

Impressive clinical results speak for themselves. For patients with advanced pancreatic cancer, traditional chemotherapy only delivers a median overall survival of 6.7 months. Treated with Daraxonrasib, the figure doubled to 13.2 months, cutting the death risk by 60%. This breakthrough brings a promising new targeted therapy against this deadly malignancy.

Keeping pace with the latest research, Chemscene has launched a full lineup of innovative structural building blocks. Many items are available at kilogram scale.

Explore our portfolio: 🌐 www.arctomsci.com
Business inquiry: 📩 [email protected]

#ASCO2026 #DrugDiscovery #MolecularGlue #Oncology #PancreaticCancer #ChemicalIntermediates #Chemscene

Originally posted on LinkedIn: 2026-06-12 (UTC; date derived from the LinkedIn activity ID).

Source: ChemScene on LinkedIn